In this way, GdOFBAu could successfully deliver Bcl9 peptides to MC38 tumor-bearing mice to inhibit tumor growth and increase the response of mice against anti-PD1 while exhibiting favorable biosafety and biocompatibility at the same time. This evidence concerns the gene BCL9 and neoplasm.